|
To: APIXABAN |
To: EDOXABAN | To: RIVAROXABAN | To: DABIGATRAN |
Switching from: DABIGATRAN |
Stop dabigatran Start apixaban when next dose of dabigatran was due |
Stop dabigatran Start edoxaban when next dose of dabigatran was due |
Stop dabigatran CrCL ≥50 mL/min: start rivaroxaban 24 hours after last dose of dabigatran. CrCL 30 to 49mL/min: start rivaroxaban 48 hours after last dose of dabigatran. CrCL <30mL/min: start rivaroxaban 3 to 4 days after last dose of dabigatran. |
⊗ |
Switching from: |
Stop rivaroxaban Start apixaban when next dose of rivaroxaban was due |
Stop rivaroxaban Start edoxaban when next dose of rivaroxaban was due |
⊗ |
Stop rivaroxaban Start dabigatran 24 hours after last rivaroxaban dose |
Switching from: EDOXABAN |
Stop edoxaban Start apixaban when next dose of edoxaban was due |
⊗ |
Stop edoxaban Start rivaroxaban when next dose of edoxaban was due |
Stop edoxaban Start dabigatran when next dose of edoxaban was due |
Switching from: FORMULARY FIRST LINE CHOICE |
⊗ |
Stop apixaban Start edoxaban when next dose of apixaban was due |
Stop apixaban Start rivaroxaban when next dose of apixaban was due |
Stop apixaban Start dabigatran when next dose of apixaban was due |
Anticoagulant switching
This information is to provides a reasonable starting point for most patients but the clinical background of each patient must be considered before applying the guidance.
If unsure, seek specialist advice.
- The guidance only applies to patients receiving anticoagulation for prophylaxis for stroke and systemic embolism in non-valvular AF or patients treated for DVT and prevention of recurrent DVT and PE.
- For other indications, or for high-risk patients (such as those with artificial heart valves or those with target INRs above 3·0), seek specialist advice.
- Prescribers should check the BNF or SPC for further information on prescribing for each individual drug.
- Usually there is no need for parenteral anticoagulants when initiating oral anticoagulants in patients with atrial fibrillation only.
|
To: APIXABAN |
To: EDOXABAN | To: RIVAROXABAN | To: DABIGATRAN | To: WARFARIN | To: PARENTERAL ANTI-COAGULANT |
Switching from:
|
Stop warfarin and check INR the next day. Start apixaban when INR ≤2.0 |
Stop warfarin and check INR the next day. Start edoxaban when INR ≤2.5 |
Stroke & systemic embolism prophylaxis: Stop warfarin and check INR the next day. Treatment or prevention of recurrence of DVT/PE: |
Stop warfarin and check INR the next day. Start dabigatran when INR ≤2.0 Patient must be able to swallow capsule whole. Opening or chewing the capsule increases oral bioavailability and bleeding risk. |
⊗ |
Stop warfarin and check INR the next day. Give first dose parenteral anticoagulant when INR ≤2.0 |
Switching from: LMWH: Low molecular weight heparin, fondaparinux, UH: Unfractionated heparin. |
Start apixaban at the next scheduled dose of LMWH or fondaparinux Start apixaban at the same time that continuous infusion of UH is discontinued |
Stop subcutaneous LMWH or fondaparinux Start edoxaban at the time of the next scheduled dose of LMWH or fondaparinux Stop UH infusionStart edoxaban 4 hours later |
Start rivaroxaban 0 to 2 hours before the time of the next scheduled dose of LMWH or fondaparinux Start rivaroxaban at the same time that continuous infusion of UH is discontinued |
Start dabigatran 0 to 2 hours before the time of the next scheduled dose of LMWH or fondaparinux Start dabigatran at the same time that continuous infusion of UH is discontinued |
Continue parenteral anticoagulant for at least 5 days and until the INR is above the lower limit of the desired therapeutic range for 24 hours, ie 2 INRs, 24 hours apart. Stop the parenteral anticoagulant immediately if INR is greater than the upper limit of the desired therapeutic range. |
⊗ |
|
To: WARFARIN | To: PARENTERAL ANTI-COAGULANT |
Switching from: FORMULARY FIRST LINE CHOICE |
Give warfarin concurrently with apixaban using standard initial dosing for at least 2 days. After 2 days co-administration: obtain INR before next dose of apixaban (24 hours after previous dose). If INR is in target range: stop apixaban and continue warfarin. If INR is not in target range: continue warfarin and apixaban concurrently until INR is in target range, then stop apixaban. Warfarin has a slow onset of action. It may take 5 to 10 days before INR is within range. After apixaban has stopped: Monitor INR closely (eg, once a week) in the first month of warfarin treatment until 3 consecutive, stable INR values (eg, between 2 & 3). |
Stop apixaban Start parenteral anticoagulant when next dose of apixaban was due NB NOT for concurrent administration |
Switching from: EDOXABAN |
Edoxaban 60mg daily: Give edoxaban 30mg once daily with standard initial dosing of warfarin. Edoxaban 30mg daily: Give edoxaban 15mg once daily with standard initial dosing of warfarin. While on both edoxaban and warfarin: measure INR at least 3 times during first 14 days, just before edoxaban daily dose (24 hours after previous dose). Continue co-administration of edoxaban and warfarin until INR ≥2·0. Most people should be able to achieve an INR of 2 or more within 14 days of concurrent administration of edoxaban and warfarin. After 14 days, recommend: discontinue edoxaban. Continue to titrate warfarin to achieve INR between 2 & 3. After treatment with edoxaban has stopped: Monitor INR closely (once a week) in the first month of warfarin treatment, until 3 consecutive, stable INR values (eg, between 2 &3). |
Stop edoxaban Start parenteral anticoagulant when next dose of edoxaban was due NB NOT for concurrent administration |
Switching from: RIVAROXABAN |
Start warfarin and continue rivaroxaban. For the first 2 days use standard, initial dosing of warfarin, followed by warfarin dosing, guided by INR. During concurrent treatment with warfarin and rivaroxaban: Measure INR just before next dose of rivaroxaban (24 hours after previous dose). If INR is in target range (≥2) for 2 concurrent days: stop rivaroxaban and continue warfarin. If INR is NOT in target range: continue warfarin and rivaroxaban concurrently until INR is in target range. Warfarin has a slow onset of action. It may take 5 to 10 days before INR is within range. After rivaroxaban has stopped: Monitor INR closely (eg, once a week) in the first month of warfarin treatment until 3 consecutive, stable INR values (eg, between 2 & 3). |
Stop rivaroxaban Start parenteral anticoagulant when next dose of rivaroxaban was due. NB NOT for concurrent administration |
Switching from: DABIGATRAN |
Adjust the starting time of warfarin based on CrCL: CrCL ≥50 mL/min: start warfarin 3 days before planning to stop dabigatran. CrCL 30 to 49 mL/min: start warfarin 2 days before planning to stop dabigatran. After at least 2 days of concurrent treatment with warfarin and dabigatran, measure INR before next dabigatran dose. If INR is in target range: Stop dabigatran and continue warfarin. If INR is NOT in target range: Continue warfarin and dabigatran concurrently until INR is in target range, then stop dabigatran. Warfarin has a slow onset of action. It may take 5 to 10 days before INR is within range. After dabigatran has stopped: Monitor INR closely (eg, once a week) in the first month of warfarin treatment until 3 consecutive, stable INR values (eg, between 2 & 3) |
Stop dabigatran Recommend: Wait at least 12 hours after the last dose of dabigatran before switching to parenteral anticoagulant. |
Switching from:
|
⊗ |
Stop warfarin and check INR the next day. Give first dose parenteral anticoagulant when INR ≤2.0 |
Switching from: PARENTERAL ANTI-COAGULANT |
Continue parenteral anticoagulant for at least 5 days and until the INR is above the lower limit of the desired therapeutic range for 24 hours, ie, 2 INRs, 24 hours apart. Stop the parenteral anticoagulant immediately if INR is greater than the upper limit of the desired therapeutic range. |
⊗ |
Abbreviation | Meaning |
AF | Atrial Fibrillation |
DVT | Deep vein thrombosis |
PE | Pulmonary embolism |
INR | International normalized ratio |
CrCl | Creatinine Clearance |
LMWH | Low molecular weight heparins |